Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in locally advanced cervical cancer
NCT02635360Phase 2Completed
- Start
- Feb 2017
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in Cervical Cancer (CC) (2 arms). Primary endpoints: Change in Immunologic Markers Following Combination of Study Drug With Chemoradiation and Number of Participants With Dose Limiting Toxicities. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02635360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635360.